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Abstract
Background: Adherence rates of preventative medication for cardiovascular disease (CVD) have been reported as 57%, and
approximately 9% of all CVD events in Europe are attributable to poor medication adherence. Mobile health technologies,
particularly mobile apps, have the potential to improve medication adherence and clinical outcomes.
Objective: The objective of this study is to assess the effects of mobile health care apps on medication adherence and health-related
outcomes in patients with CVD. This study also evaluates apps’ functionality and usability and the involvement of health care
professionals in their use.
Methods: Electronic databases (MEDLINE [Ovid], PubMed Central, Cochrane Library, CINAHL Plus, PsycINFO [Ovid],
Embase [Ovid], and Google Scholar) were searched for randomized controlled trials (RCTs) to investigate app-based interventions
aimed at improving medication adherence in patients with CVD. RCTs published in English from inception to January 2020 were
reviewed. The Cochrane risk of bias tool was used to assess the included studies. Meta-analysis was performed for clinical
outcomes and medication adherence, with meta-regression analysis used to evaluate the impact of app intervention duration on
medication adherence.
Results: This study included 16 RCTs published within the last 6 years. In total, 12 RCTs reported medication adherence as
the primary outcome, which is the most commonly self-reported adherence. The duration of the interventions ranged from 1 to
12 months, and sample sizes ranged from 24 to 412. Medication adherence rates showed statistically significant improvements
in 9 RCTs when compared with the control, and meta-analysis of the 6 RCTs reporting continuous data showed a significant
overall effect in favor of the app intervention (mean difference 0.90, 95% CI 0.03-1.78) with a high statistical heterogeneity
(I2=93.32%). Moreover, 9 RCTs assessed clinical outcomes and reported an improvement in systolic blood pressure, diastolic
blood pressure, total cholesterol, and low-density lipoprotein cholesterol levels in the intervention arm. Meta-analysis of these
clinical outcomes from 6 RCTs favored app interventions, but none were significant. In the 7 trials evaluating app usability, all
were found to be acceptable. There was a great variation in the app characteristics. A total of 10 RCTs involved health care
professionals, mainly physicians and nurses, in the app-based interventions. The apps had mixed functionality: 2 used education,
7 delivered reminders, and 7 provided reminders in combination with educational support.
Conclusions: Apps tended to increase medication adherence, but interventions varied widely in design, content, and delivery.
Apps have an acceptable degree of usability; yet the app characteristics conferring usability and effectiveness are ill-defined.
Future large-scale studies should focus on identifying the essential active components of successful apps.
Trial Registration: PROSPERO International Prospective Register of Systematic Reviews CRD42019121385;
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=121385
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Introduction
Cardiovascular diseases (CVDs) are responsible for almost
one-third of all deaths worldwide, leading to an estimated 17.9
million deaths each year [1]. A long-term use of cardiovascular
medications significantly reduces the risk of morbidity and
mortality [2,3], but their full therapeutic potential cannot be
achieved if patients are nonadherent [4]. Approximately 9% of
all CVD events in Europe are attributed to poor medication
adherence [5], with adherence rates of only 57% [6].
Developing interventions to tackle medication nonadherence is
important for improving health outcomes. A recent network
meta-analysis of many different interventions showed that those
with a technology-based approach had a positive, but short-lived,
effect on medication adherence [7]. The escalating inclusion of
technology into everyday life has witnessed the introduction of
mobile health (mHealth) interventions, such as mobile apps, to
support patients and health care professionals (HCPs) in disease
management [8,9]. These reviews were not confined to
app-based interventions. Some of the wide-ranging interventions
included apps, whereas other mHealth interventions, such as
text messaging and emails, were common. Several systematic
reviews have indicated that apps may play a role in improving
medication adherence in patients with CVD. For example, one
systematic review included smartphone app-based interventions
to promote lifestyle and behavior changes, reporting them as
effective at improving medication adherence and increasing
physical activity behavior [10]. For secondary prevention in
patients with cerebrovascular disease, another systematic review
showed improved medication adherence, a better maintenance
of blood pressure (BP) and lipids within target ranges, and
decreased episodes of angina, transient ischemic attack, and
stroke with mHealth interventions, several of which included
apps [11]. In contrast, a systematic review of internet-based
interventions, which included apps, improved dietary outcomes,
quality of life (QoL), and physical activity but reported a lack
of evidence for their effect on medication adherence [12].
Published evidence for the beneficial effects of apps on
medication adherence is often lacking or inconclusive. This
study evaluates the effectiveness of app-based interventions on
medication adherence in patients with CVD. Furthermore, this
study explores the effects of app-based interventions on
health-related outcomes, the functionality and usability of apps
for patients, and the involvement of HCPs in the delivery of the
intervention.
Methods
Search Strategy and Study Selection
This review followed the PRISMA (Preferred Reporting Items
for Systematic Reviews and Meta-Analyses) guidelines [13].
The protocol was registered in the PROSPERO database
(CRD42019121385) [14].
MEDLINE (Ovid), PubMed Central, Cochrane Library,
CINAHL Plus, PsycINFO (Ovid), Embase (Ovid), and Google
Scholar databases were searched from inception to January 2020
using a 3-domain search strategy to include terms related to
CVD, apps, and medication adherence (the search strategy is
presented in Multimedia Appendix 1). Studies were selected if
they were randomized controlled trials (RCTs), if they were
published in English, if they were for patients with CVD (eg,
atrial fibrillation, coronary heart disease, heart failure,
hypercholesterolemia, hypertension, myocardial infarction, and
stroke), and if the intervention included an app to improve
medication adherence. A 2-stage process was used to select
studies for inclusion in this review. First, 1 author (SA) screened
titles and abstracts for relevance and removed duplicate records.
Where ambiguities arose from the screening process, 1 of 2
different authors (JM and ZJ) independently assessed the title
and abstract for relevance. For the second stage of screening, 2
authors (SA and ZJ) independently reassessed the full-text
studies matching the prespecified criteria for eligibility.
Bibliographies of selected studies were hand searched for
additional references.
Data Extraction and Quality Assessment
Data extraction was conducted using a standardized form
developed specifically for this review. Extracted data included
the characteristics of the study and details of the intervention
strategy. Quality assessment was conducted independently by
2 authors (SA and ZJ), and consensus was reached through
discussion. The risk of bias was guided by the Cochrane
Collaboration tool for RCTs [15], with the bias broadly
categorized as selection, performance, attrition, or other bias.
Once categorized, each bias domain was further categorized as
low, high, or unclear risk of bias. Agency for Healthcare
Research and Quality standards [15] were then applied, and an
overall summary was generated using Review Manager
(RevMan. version 5.4, The Cochrane Collaboration) [16].
Data Synthesis and Statistical Analysis
The outcome data were extracted from each trial. The authors
were contacted for raw data where follow-up points for
individual trials were identified but outcomes not reported in
the published manuscripts. Four main analyses were conducted:
(1) a series of meta-analyses of intervention effects on
medication adherence at different time points of intervention
duration; (2) a univariable meta-regression analysis, regressing
the app intervention across trials on intervention duration; (3)
a meta-analysis of intervention effects on medication adherence
across all included trials at the final time point of intervention
duration; and (4) a series of meta-analyses of intervention effects
on systolic blood pressure (SBP), diastolic blood pressure
(DBP), total cholesterol (TC), and low-density lipoprotein
cholesterol (LDL-C) levels at the third month of the intervention.
For the meta-analyses, trials reporting continuous data, means,
SD, and sample sizes were included. Where SE or CI were
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reported, the SD was manually calculated. A random-effects
model was used to allow for differences in the true intervention
effect across trials. The Q test was used to assess heterogeneity,
with a significant result (P<.05) indicating heterogeneity across
trials. The I2 statistic was computed to describe the percentage
of variability effect estimates due to heterogeneity. I2 values of
25%, 50%, and 75% were assigned as low, moderate, and high
heterogeneities, respectively [17]. The statistical package
STATA (StataCorp, Stata Statistical Software: Release 16) was
used for the meta-analysis [18].
Results
Search Results
Searches yielded 2269 citations, of which 590 duplicates were
removed. The title and abstract screening resulted in 27 full-text
review studies. Of these, 11 studies were excluded. No
additional citations were identified by hand searching. Therefore,
16 RCTs were included in this review [19-34]. A PRISMA
flowchart summarizing the study selection is shown in Figure
1.
Figure 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram depicting study selection.
Study Characteristics and Design
All the included studies were published between 2013 and 2019.
They all compared 1 or more interventions (app alone or app
in conjunction with a package of participant support) with a
control arm described as usual care. A total of 10 studies
randomized patients to parallel intervention or control groups
[20,21,23,25-28,31-33]; 2 had a crossover design [19,30]; and
4 were cluster randomized by the trial site [22,24], researcher
[29], or physician [34]. Study sample sizes ranged from 24 [30]
to 412 [31], and interventions ranged in duration from 1
[23,30,32] to 12 [29] months. The definition of usual care in
the control groups differed among the studies. It was defined
as follow-up without the use of the app in 7 trials
[22,24,26,27,29,31,33]; the use of the app with limited
functionality in 1 trial [32]; and an alternative intervention not
including apps, for example, the use of a SMS text message
[20,28,34], follow-up phone calls [21], use of a pillbox [23],
and use of an e-diary [25] in 6 trials. For the 2 crossover trials,
nondigital technology methods were used [19,30] (Table 1).
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Table 1. Characteristics of the included randomized controlled trials.
Primary and secondary outcomes
measures
Length of inter-
ventionIntervention and control arm
Number of random-
ized participantsRCTa designSource; country
20 weeks77Crossover 2-
arm
Brath et al [19];
Austria




• Secondary: changes in SBPb,• Control: control phase using
paper diary DBPc, HbA1cd, LDL-Ce, and
usability of the app
9 months54Parallel 2-armChandler et al
[20]; United
States
• Primary: change in SBP• Intervention: SMASHf app
• Secondary: change in DBP,
medication adherence, and
patients’ satisfaction with us-
• Control: SMS text messages
on lifestyle tips unrelated to
medication adherence
ing the app
6 months280Parallel 3-armFang and Li
[21]; China
• Primary: medication adher-
ence
• Intervention: 2 arms: (1)
SMS text messages using an
app and (2) SMS text mes- • Secondary: none






Frias et al [22];
United States
• Primary: change in SBP• Intervention: a DMOg system
designed to provide feedback
about taking medication to
• Secondary: changes in SBP,
DBP, HbA1c, and LDL-C;
medication adherence; andboth patients and providers
satisfaction with using theconsisted of an ingestible
appsensor, sensor patch, and app,
2 arms: (1) 4-week DMO and
(2) 2.12-week DMO






• Primary: medication adher-
ence
• Intervention: 2 arms: (1)
mHealthh app reminder and
(2) mHealth app silent • Secondary: acceptance of the
app• Control: 2 arms: (1) tele-
health (pillbox reminder) and




Guo et al [24];
China
• Primary: medication adher-
ence, usability of the app,
PAMi, patients’ knowledge,
• Intervention: mAF app




6 months174Parallel 2-armJohnston et al
[25]; Sweden
• Primary: medication adher-
ence
• Intervention: interactive pa-
tient support tool (web-based
app) • Secondary: change in SBP
and LDL-C; QoL; and usabil-• Control: no app use, only
simplified tool ity of the app
6 months95Parallel 2-armKim et al [26];
Republic of Ko-
rea
• Primary: medication adher-
ence, PAM, SBP, and DBP
• Intervention: Wireless Self-
Monitoring, an app with en-
rolled in the HealthyCircles
Platform
• Secondary: none
• Control: no app use
12 weeks28Parallel 2-armLabovitz et al
[27]; United
States
• Primary: medication adher-
ence
• Intervention: artificial intelli-
gence app
•• Secondary: medication adher-
ence for patients receiving
Control: no daily monitoring
DOACsk and usability of the
app
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Primary and secondary outcomes
measures
Length of inter-
ventionIntervention and control arm
Number of random-
ized participantsRCTa designSource; country
• Primary: HDL-Cl, LDL-C,
TCm, and triglyceride
• Secondary: medication adher-
ence
12 weeks• Intervention: HeartGuardian
app and weekly text mes-
sages on health education
• Control: weekly SMS text
messages on health education
57Parallel 2-armLiu et al [28];
China
• Primary: medication adher-
ence
• Secondary: SBP and DBP
12 months• Intervention: AlerHTA app






eras et al [29];
Spain
• Primary: medication adher-
ence
• Secondary: user experience
of the app
28 days• Intervention: medication app





• Primary: medication adher-
ence and change in SBP
• Secondary: SBP and DBP
12 weeks• Intervention: Medisafe app
• Control: no intervention
412Parallel 2-armMorawski et al
[31]; United
States
• Primary: medication adher-
ence and heart rate, SBP, and
DBP
• Secondary: acceptability of
the app
30 days• Intervention: BB app and
WeChat app
• Control: WeChat app
50Parallel 2-armNi et al [32];
China
• Primary: medication adher-
ence
• Secondary: BPn, TC, LDL-C,
and acceptability of the app
3 months• Intervention: 2 arms: (1) ba-
sic medication reminder app
and (2) advanced medication
reminder app
• Control: standard care as de-
termined by patients’ physi-
cians
166Parallel 3-armSanto et al [33];
Australia
• Primary: BP




score for glucose control, pa-
tients’ satisfaction with using
the app, side effects of antihy-
pertensive medications, hyper-
tension, and stroke knowl-
edge
3 months• Intervention: Blue-toothed
UA-767Plus BT BP device
and a smartphone with an
embedded app
• Control: SMS text messages




Sarfo et al [34];
Ghana
aRCT: randomized controlled trial.
bSBP: systolic blood pressure.
cDBP: diastolic blood pressure.
dHbA1c: glycated hemoglobin.
eLDL-C: low-density lipoprotein cholesterol.
fSMASH: Smartphone Med Adherence Stops Hypertension.
gDMO: digital medicine offering system.
hmHealth: mobile health.
iPAM: patient activation measure.
jQoL: quality of life.
kDOAC: direct oral anticoagulant.
lHDL-C: high-density lipoprotein cholesterol.
mTC: total cholesterol.
nBP: blood pressure.
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The included trials covered a range of different CVDs and risk
factors: atrial fibrillation [24], coronary heart disease
[21,30,32,33], diabetes [19,22], heart failure [23],
hypercholesterolemia [19], hypertension [19,20,22,26,29,31],
myocardial infarction [25,28,30], and stroke [27,34]. The mean
age of participants varied depending on the disease and ranged
from 46.5 (SD 9.9) [20] to 73.8 (SD 7.5) years [30]. All studies
recruited outpatients from secondary care
[19,21,23-28,30,32,34], primary care [20,22,29], tertiary care
[33], or web-based patient communities [31].
App Characteristics
The characteristics of the trialed apps are shown below. Each
study used a different app developed by different organizations:
8 were academic or government institutions
[20,21,23,24,26,28-30], whereas others were commercial
organizations. A total of 7 apps were supported by platforms
[19-22,24,26,27]. The functionality of the apps and platforms
varied across the different trials and the interactions needed by
patients. All but 2 apps [24,26] delivered medication reminders
to promote medication adherence. For the majority, this was
their primary function, with 4 apps using one-way SMS text
message reminders [21,27,28,32] and 5 delivering a mobile
device alert [23,29-31,33]. Others had a primary focus on
self-monitoring alone [26] or with a medication reminder [25],
patient education [24], or delivery of a tailored motivational
SMS text message based on medication adherence levels
[20,34]. Two trials used the app to transmit patients’ adherence
data to the associated platform to be monitored by HCPs [19,22].
Involvement of HCPs
Half of the trials involved physicians and/or nurses in app use
[19,21,24,25,29,30,32,34] (Table 2). A trial involved
pharmacists in blinding study medication, whereas the health
care team, whose professions remained unspecified, used the
app and monitored the data transmitted to the associated
platform [22]. One trial permitted the sharing of patients’ data
with families and caregivers as well as with HCPs [26]. A total
of 6 trials did not specify the type of HCPs involved in app use
[20,23,27,28,31,33]. The involvement of HCPs varied; most of
the trials involved HCPs to monitor patients’ data
[19,22,24-26,30,34], instruct patients on how to use the app
[29], and send educational materials to patients via the app
[21,32].
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Table 2. Mobile app characteristics in the included randomized controlled trials.
Involvement of HCPaOverall system
functionality
Platform used with the app and func-
tionality
App name and functionalitySource
PhysicianReminderRemote telemonitoring service: data
sent from the app to platform and then
Name not specified, referred to as a mobile
phone–based data gateway. Reader and trans-
Brath et al
[19]
analyzed for timing and number ofmitter of data from electronic medication blis-
ter to a remote database pills taken, and an automatic reminder
is sent to patients via SMS text mes-
sages
Not statedReminderHIPAAd-compliant servers: BP data
sent from the app to platform, then
SMASHb app: medication reminders via sig-
nals (blinking light, intermittent chime, auto-
Chandler et al
[20]
analyzed for processing with times-mated SMS text messages, or phone call) and
tamps, providing information for theBPc monitor reminders via SMS text messages.
calculation of adherence levels to the
BP protocol
The app provided timely tailored motivational
and reinforcement SMS text messages based
on the levels of medication adherence and SMS
text message reminders to monitor BP with a
Bluetooth-enabled BP device. The app also
provided a cumulative table of average BP
displayed in categories of daily, weekly, and/or
monthly progress reports
Physician and nurseReminder and
education
Huaxi-gold card: the platform sent
SMS text messages, images, media
content related to disease and other
information at regular intervals
Name not specified, referred to as a messaging
app: medication reminders via an SMS text





had a role in set up (coen-
Reminder and
education
Provider web portal: provider views
summaries of the DMOe data for the
patients on the web portal
Proteus Discover app: reader and transmitter
of the patient’s adherence data from patch to
the cloud and prompted the patient to take their
medication doses as scheduled. Patients could
Frias et al [22]
capsulation of ingestible
sensor and medication)




No platformName not specified, referred to as a medication
adherence app. Medication reminders provided
via alert, patients could view list of medications
Goldstein et al
[23]
with instructions, and they were able to record
taking their medication
PhysicianEducationCloud platform: data managementmAF app: educational app used by both pa-
tients and physicians: For patients, personal
Guo et al [24]
health record (CHA2DS2-VAScf, HAS-
BLEDg, and SAMe-TT2R2h scores), patient
educational programs (knowledge of atrial
fibrillation and learn how to manage them-
selves at home), patient involvement in self-
care items (monitor their heart rate, BP, and
their quality of life), and structured follow-up
consultation via a sent alert reminder. For
physicians, clinical decision support
Physician and nurseReminder and
education
No platformName not specified, referred to as an interac-
tive patient support tool app: medication re-
minders via SMS text messages (e-diary) to
Johnston et al
[25]
register daily ticagrelor intake. Secondary pre-
vention educational modules (exercise module,




EducationHealthyCircles platform: the platform
sent reminders for self-monitoring
BP, education information about the
disease condition, and general health
behavior recommendations
HealthyCircles: an educational app that al-
lowed patients and nurses to access the pa-
tient’s reading recorded on the BP monitor
devices. The BP measurements are wirelessly
uploaded from BP devices to the HealthyCir-
cles account
Kim et al [26]
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Involvement of HCPaOverall system
functionality
Platform used with the app and func-
tionality
App name and functionalitySource
Clinic staff (profession not
specified)
ReminderArtificial intelligence platform: the
platform sent an automatic SMS text
message or emails to clinical staff if
doses were missed, late, or based on
incorrect use
Artificial intelligence app: medication re-
minders and dosing instructions via SMS text
messages. Late doses generated notifications






No platformHeartGuardian app: medication reminders via
SMS text messages. The app provided educa-
tional materials; medication recording and
daily feedback; and self-empowerment via au-
tomatic intelligent, real-time video feedback
based on the subjects’ medication adherence
Liu et al [28]
PhysicianReminder and
education
No platformAlerHTA app: medication and appointments
reminders via alerts. The app recorded patients’
personal data, the physician’s advice about the
prescribed treatment, and the results of the BP





PhysicianReminderNo platformiNephro medication plan app: medication re-
minders via alert, to support the drug intake




Not statedReminderNo platformMedisafe app: medication reminders via alert.
The app provided alerts to remind patients
when it is time to take medications and gener-
ate weekly adherence reports, the app also al-




Physician and nurseReminder and
education
No platformBB reminder app and WeChat app: medication
reminders via SMS text messages through the
BB reminder app. Educational materials
through the WeChat app
Ni et al [32]
Not statedReminderNo platformNo specified name. Referred to as a medication
reminder app. Medication reminders provided
via alert. In the basic app, the reminders were
noninteractive and occurred 1 time only,
whereas the advanced app provided interactive
and customizable features including daily re-
minders, which could be snoozed, rescheduled,
and/or marked as a taken or missed dose;
medication refill reminders; adherence statis-
tics; and ability to share information with oth-
ers such as family members, if the patient
missed a medication dose
Santo et al
[33]
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Involvement of HCPaOverall system
functionality
Platform used with the app and func-
tionality
App name and functionalitySource
NurseReminderNo platformNo specified name. Referred to as medical
regimen assistance app. Medication reminders
provided via SMS text messages. The app re-
ported BP measurements and medication intake
and sent written and oral information on adher-
ence criteria to take the medications within 2
hours of designated times and to measure BP
every 3 days in the morning and evening
Sarfo et al
[34]
aHCP: health care professional.
bSMASH: Smartphone Medication Adherence Stops Hypertension.
cBP: blood pressure.
dHIPAA: Health Insurance Portability and Accountability.
eDMO: digital medicine offering system.
fCHA2DS2-VASc: congestive heart failure, hypertension, age>75 years (doubled), type 2 diabetes mellitus, previous stroke, transient ischemic attack
or thromboembolism (doubled), vascular disease, age of 65-75 years, and sex.
gHAS-BLED: Hypertension, abnormal renal or liver function, stroke, bleeding history or predisposition, labile international normalized ratio, age>65
years, drugs or alcohol concomitantly.
hSAMe-TT2R2: sex, age, medical history, treatment, tobacco use, and race.
Assessment of Medication Adherence
Adherence measures varied among studies (Multimedia
Appendix 2 [19-34]). Most used questionnaires to include the
validated 8-item Morisky Medication Adherence Scale
[20,26,31,33] and the 4-item Morisky Medication Adherence
Scale [21,28] and nonvalidated self-report questionnaires
[24,25,30,32]. Other adherence measures included medication
event monitoring systems (MEMSs) [29] and a digital medicine
offering with an ingestible sensor taken alongside medication
[22]. Other trials used a combination of measures; 2 trials
combined 2 different measures, one for each arm. One trial used
the remote medication adherence measurement system for the
intervention and pill count for the control [19]. Another trial
used an electronic self-report for the intervention and pillbox
openings for the control [23]. Only 2 trials combined 2 different
measures for both arms (pill counts and plasma samples [27]
and pill counts and 8-item Morisky Medication Adherence Scale
[34]).
Effect on Medication Adherence
Overall, 12 trials reported apps to enhance medication adherence
rates [20,21,24,25,27-34], with 9 demonstrating significant
improvement [20,24,25,28-31,33,34]. In the remaining 4 trials,
3 did not find a significant difference [22,23,26] and 1 reported
a significant difference, with only 1 of the 4 medicines being
monitored [19] (Multimedia Appendix 2 [19-34]). Six trials
reporting continuous data were included in the meta-analysis
of medication adherence [20,26,30,31,33,34]. Trials with the
same duration of follow-up for the intervention were subjected
to a separate meta-analysis and all favored the intervention,
mean difference for month 1, 1.52 (95% CI 0.89 to 2.15); 2
trials [20,30] for month 3, 0.46 (95% CI 0.21 to 0.71); 4 trials
[20,31,33,34], for month 6, 1.46 (95% CI −1.02 to 3.95); 2 trials
[20,26], and for month 9, 1.49 (95% CI −1.42 to 4.40); 2 trials
[20,34]. Meta-regression analysis for these 6 studies showed
that the duration of intervention (ie, the follow-up month) did
not exert a statistically significant impact on the effect of the
app on medication adherence (P=.65). Thus, a combined
meta-analysis (Figure 2) over the different trial durations was
performed, thereby demonstrating a significant effect in favor
of the app intervention (mean difference 0.90, 95% CI 0.03 to
1.78) with a high statistical heterogeneity (I2=93.32%).
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Figure 2. Meta-analysis results and forest plot of the effect of app-based interventions on medication adherence. Mean difference (95% CIs) are denoted
by black boxes (black lines). The combined mean difference estimate for all studies is represented by a black diamond, where diamond width corresponds
to 95% CI bounds. REML: restricted maximum likelihood.
Effect on Other Nonclinical Outcomes
An array of nonclinical outcomes was measured across the trials.
Two trials have reported patient activation measures (PAMs)
[22,26]. One trial reported a higher increase in PAM scores
mean change for the intervention arm 7.9 (SE 2.4) when
compared with control 1.7 (SE 3.3); mean difference 6.2 (SE
4.6), (95% CI −2.8 to 15.2) [22]. However, for the other trial,
there was no significant difference in the average PAM score
over the trial period (baseline: 78.0; end of trial: 76.0; P=.34)
[26]. Patients’ knowledge of their CVD was only reported in 2
trials [24,34], despite 9 of the 16 trials involving apps with an
educational function [21-26,28,29,32]. Interestingly, one trial
showed not only a significant improvement in knowledge with
app use but also in medication adherence [24]. In the same trial,
the benefits and burden of anticoagulation therapy were explored
using a patient satisfaction questionnaire. Patients using the app
expressed more anticoagulant benefits, whereas the control
declared more burden: benefit (intervention: mean 15.6, SD
2.73 vs control: mean 14.21, SD 3.37; P=.05) and burden
(intervention: mean 15.57, SD 6.57 vs control: mean 19.30, SD
6.39; P=.008) [24]. In the other trial, the knowledge
questionnaire scores increased at the end of the trial but not
significantly (intervention: mean 10.8, SD 0.8 vs control: mean
11.1, SD 1.1; P=.23) [34]. The QoL was assessed in 2 trials
using the European Quality of Life–5 Dimensions measure
[24,25]. One trial reported significantly higher QoL in the
intervention arm compared with the control (P<.05; exact P
value not quoted in original paper) [24], whereas in the other
trial, QoL scores increased with app use over the duration of
the trial but not significantly (P=.06) [25].
Effect on Clinical Outcomes
Clinical outcomes measured included BP, blood cholesterol,
and blood glucose (Multimedia Appendix 3
[19,20,22,25,26,28,29,31-34]). Eight trials reported positive
effects of apps on both SBP and DBP [19,20,22,25,26,29,33,34],
and 4 reported significant results [19,20,22,29]. In total, 4 trials
reported improvements in TC [19,22,28,33] and 3 were
significant [19,22,28]. A reduction in LDL-C was observed
with app-based interventions [19,22,25,28,33], but it was only
significant in 2 trials [22,25]. Only 2 trials reported glycated
hemoglobin (HbA1c) as an outcome, with no significant change
[19,22]. Meta-analysis for clinical outcomes was only possible
at 3 months duration of intervention for SBP, DBP, TC, and
LDL-C; all favored the use of an app in disease management,
but not all were significant (Multimedia Appendix 4
[22,25,28,31,33,34]). Meta-analysis for HbA1c was not possible
because of the lack of reported outcomes.
App Usability, Acceptability, and Patient Satisfaction
Various questionnaires were used to evaluate the app usability
for patients, but this was only done in 4 trials [19,24,25,27].
One study used a validated System Usability Scale to
demonstrate greater usability in the app intervention arm than
in the control arm (intervention: mean 87.3, SD 13.9 vs control:
mean 78.1, SD 18.9; P=.001) [25]. Three trials evaluated app
usability with nonvalidated questionnaires and obtained positive
feedback from 80% or more of the participants [19,24,27].
Patients with stroke rated the app extremely good as a
medication management tool and as means to improve
physician-patient rapport [27]. Patients with atrial fibrillation
agreed that the study app was user-friendly and helpful with
additional positive feedback from physicians [24].
Four different trials explored app acceptability in patients
[23,30,32,33]. Acceptance rates measured by nonvalidated
questionnaires found the app to be more acceptable than the
control [23], and most patients reported that the app was useful
and helpful [33]. Interviews conducted within 2 studies revealed
that patients accepted and appreciated receiving reminders and
educational materials via the app [32] and that most patients
(22/24) reported wanting to use the app in everyday life [30].
Three trials evaluated patient satisfaction with the apps being
trialed by nonvalidated questionnaires, with more than 90%
reporting the app as easy to use [20,22,34].
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Risk of Bias of Included Trials
Only 7 trials reported sufficient random sequence generation
[21,23,29,31-34], and only 3 trials reported allocation
concealment [26,33,34]. Although these types of interventions
are problematic to blind, outcome assessors could have been
blinded, but only 5 trials clearly stated that this was done
[24,28,31,33,34]. In total, 14 trials had a low risk of incomplete
outcome data [19-23,25-31,33,34], whereas only 5 had a low
risk of selective outcome reporting [20,25,31,33,34]. Ten trials
h a d  n o  o t h e r  s o u r c e s  o f  r i s k  o f  b i a s
[19,20,23,24,26,27,29,32-34]. According to the Agency for
Healthcare Research and Quality standards, most trials were
considered to be of poor quality [19-32], with only 2 rated as
fair [33,34]. Figures 3 and 4 present the risk of bias judgment.
Figure 3. Authors’ judgments about each risk of bias item for each included trial. Green: low risk of bias; yellow: unclear risk of bias; red: high risk
of bias.
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Figure 4. Authors’ judgments about each risk of bias item presented as percentages across all included trials.
Discussion
Principal Findings
This study included 16 RCTs that assessed the effectiveness of
mobile app–based interventions on medication adherence
[19-34]. A total of 9 trials showed a statistically significant
improvement in medication adherence in the intervention arm
[20,24,25,28-31,33,34]. The meta-analysis of 6 trials revealed
that app interventions exert a significant positive effect on
medication adherence with meta-regression, showing no
statistically significant impact for the duration of use over a
maximum of 9 months. However, the statistical and
methodological heterogeneity was high [20, 26, 30, 31, 33, 34].
Ten trials assessed health-related outcomes and generally
reported an improvement with intervention over control
[19,20,22,24-26,28,29,33,34]. The apps used had mixed
functionality, including reminders [19,20,27,30,31,33,34],
education [24,26], or both [21-23,25,28,29,32]. Regarding the
involvement of HCPs, most involved physicians and/or nurses
[19,21,24,25,29,30,32,34]. The usability of apps was mainly
assessed with questionnaires, with most participants reporting
acceptance and ease of use [19,24,25,27]. The effectiveness of
app interventions could not be assigned to particular app
components or characteristics. Half of the trials were small-scale
studies, that is, pilot studies [19,22,24,34] and feasibility studies
[21,23,27,32], and most trials were classified as having poor
quality of evidence because of the high risk of bias or
insufficient reporting of information [19-32].
Relationship With Previous Published Literature
Previous systematic reviews have assessed the effectiveness of
health care apps in the management of several different
long-term conditions, including asthma [35], obesity and
diabetes [36], and CVD [37]. Most included small-scale studies,
with insufficient or low-quality evidence to support app use.
Despite this, many reviews have reported beneficial trends, for
example, in the promotion of positive behavior changes such
as medication adherence [37].
A network meta-analysis of different interventions showed that
technology-based interventions exert a major effect on the
long-term management of medication adherence in patients
with CVD [38]. The World Health Organization categorizes
medication adherence measurements as either subjective or
objective [39]. More than half of the trials in this systematic
review used subjective self-report questionnaires to measure
medication adherence [20,21,24-26,28,30-33], with a potential
to overestimate adherence. Although there is no gold standard
measure of medication adherence, a multi-measure approach is
highly recommended to reduce subjectivity [40]. Therefore, the
results of improved adherence from the trials included in this
review should be interpreted with caution.
This review shows that objective measures can be improved
with expected app use. For example, some of the trials included
in this review assessed BP and showed improvements for
participants in the intervention arms [19,20,22,25,26,29,33,34],
a similar result to a previous systematic review assessing the
effects of mobile apps designed for BP management [9]. Another
systematic review and meta-analysis of 21 RCTs showed a
reduction in HbA1c levels in patients with diabetes [41]. In this
review, the effectiveness of apps to support patients with
diabetes was inconclusive, as only 2 included trials evaluated
HbA1c, and both the trials reported no significant difference in
the change in HbA1c between the intervention and control arms
[19,22].
Although few trials included in this review investigated
nonclinical outcomes other than adherence, those that did
demonstrated a meaningful, but not always significant,
improvement in PAM [22,26], patients’ disease knowledge
[24,34], anticoagulation satisfaction [24], and QoL [24,25].
These results align with existing systematic reviews of
smartphone-based health care technologies, which demonstrate
that apps could play an important role in patient education,
self-management, and remote monitoring [42] and improvements
in patients’ QoL [37]. Furthermore, 2 pilot studies examining
the feasibility of app use to enhance safe anticoagulation therapy
and knowledge acquisition by patients showed a significant
increase in anticoagulation knowledge after 3 months of app
use [43,44]. The beneficial effects of apps on medication
adherence will likely depend on the nature of the support needed
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by different patients. To improve medication adherence, the
literature suggests that some patients may need only reminders,
whereas others need a greater knowledge and understanding of
their disease and the medication prescribed [45,46]. There is a
long history of reminders and patient education to improve
medication adherence, and the introduction of app technology
has seen these strategies incorporated into mHealth
interventions. In this review, most of the included trials used
apps with mixed functionality, including reminders, education,
or both. All but 2 of the apps [24,26] included reminders
[19-23,25,27-34]; of these, significant improvements in
medication adherence were only reported in about half of the
trials [20,24,25,28-31,33,34]. Thus, it remains impossible to
assign success to a single component within a multifunctional
intervention.
App design, user interface, and evaluation of these factors are
often under-reported. In this review, 4 trials that assessed app
usability demonstrated that the apps were user-friendly, and
users were interested and engaged with the technology
[19,24,25,27]. Three of these studies featured commercially
developed apps [19,25,27]. The measures of app success for
developers of commercial, academic, or government origins
may explain why only 1 app developed by an academic
institution [24] investigated usability. A systematic review of
app usability in patients with diabetes also reported moderate
to good usability, but users expressed preference for apps
developed for tablet computers rather than smartphones due to
their larger display and better illustrations [47]. Usability is a
key factor in the uptake of mHealth apps [48,49], and it would
make sense to conclude that a more user-friendly app might be
more effective. In this review, significant improvements in
medication adherence rates were found in only 2 of the 4 trials
reporting a good usability [24,25]. This may, in part, be because
usability outcomes measure ease of use (ie, user-friendliness)
rather than motivation, engagement, and continued use.
Motivating components, such as social contracts with family
members and gamification, have been incorporated into some
apps to improve their effectiveness [43]. Several studies
highlight the importance of using theory to develop and design
behavioral change interventions [50-52], which should also be
considered in mHealth app intervention design. Only 3 of the
trials in this review [20,28,34], reported the use of behavioral
change theories to inform their app intervention, and it is of
note that only one of the app interventions purported to involve
social support or interactions outside of HCPs [26]. This review
revealed that HCPs’ involvement in app interventions for CVD
health care mainly involved physicians and nurses
[19,21,24,25,28-30,32,34], with 1 trial reporting pharmacist
involvement; however, that did not include the administration
of the app intervention [22]. With the widening clinical
patient-facing roles of pharmacists within primary care [53,54]
and reports of their effectiveness in both CVD management
[55-57] and successful efforts to improve CVD medication
adherence [58,59], it is potentially surprising that pharmacists
were not more involved in any of these studies. The involvement
of any HCP in the administration and concomitant use of apps
with patients requires careful consideration. Such apps have the
potential to increase HCP workload, and it remains unclear
whether the cost of that involvement outweighs the benefits
observed. Of the RCTs included in this review, 5 of the 9 that
included HCPs in the administration of the app reported
significant improvements in medication adherence, but no
cost-benefit analysis was conducted [24,25,29,30,34]. In the
current climate, with a growing choice of apps, a more important
role for HCPs may be in the recommendation of safe,
user-friendly, and effective mHealth apps for patients depending
on their disease and apps chosen specifically to meet their
patients’ needs and motivations.
Strengths and Limitations
This review did not consider the differences in adherence
between the medications included in the trials. Some
medications might have a higher rate of nonadherence than
others because of the adverse effects and taste of the
formulation. The heterogeneity of the trials’ methodologies,
apps, and outcome measures studied made quantitative
comparisons problematic. Different measures of medication
adherence were used among the trials, which made it impossible
to calculate the exact adherence rates. For several of the included
trials, control groups were also subjected to an intervention
aimed at improving medication adherence, meaning that the
impact of the app intervention was not comparable with standard
care. This, coupled with the potential for wide variations in
standard care more generally, suggests that the findings of many
of the included studies need to be interpreted with caution.
Finally, this review included only RCTs; thus, other relevant
studies and reports from the gray literature were excluded.
However, RCTs are considered the cornerstone of clinical
research to determine the efficacy of interventions and the
highest level of evidence.
Implication for Practice and Policy
Health care apps have the potential to enhance medication
adherence, leading to improvements in clinical and nonclinical
outcomes in patients with CVD. However, the use of this
technology to support medication adherence is in its infancy,
and apps require robust testing to demonstrate its effectiveness.
The trials included in this review provided inconsistent data
regarding their effectiveness. Overall, user engagement and
usability were rated positively, demonstrating interest in the
concept. However, it is difficult to make strong, unrestricted
recommendations for practice, especially with the
methodological limitations of the included trials.
Implication for Research
This review indicates the need for further large-scale studies to
determine whether mobile apps are effective in improving
medication adherence among patients with CVD. There is a
paucity of data to differentiate the effects of individual app
intervention characteristics on behavioral change, and the most
effective app functionality remains unknown. The involvement
of HCPs in the use of mobile apps needs to be investigated
further, needs to undergo cost-benefit analysis, and needs to be
compared with the effectiveness standalone apps that do not
require HCP input. Finally, a standard validated approach for
medication adherence measurement is recommended for future
studies to enable the comparison of findings and/or pooling of
adherence data.
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Mobile apps appear to enhance medication adherence and
improve health-related outcomes. Apps have an acceptable
degree of usability; yet the app characteristics conferring
usability and effectiveness are often indeterminate due to their
multifactorial design. Existing evidence is currently insufficient
to unreservedly recommend the use of health care apps to
improve adherence to CVD medications because of the generally
small sample sizes; clinical and methodological heterogeneity
between studies; and disparity in app features, content, and
delivery, but they may enhance medication adherence as part
of a package of care.
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DBP: diastolic blood pressure
HCP: health care professional
LDL-C: low-density lipoprotein cholesterol
mHealth: mobile health
PAM: patient activation measure
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses
QoL: quality of life
RCT: randomized controlled trial
SBP: systolic blood pressure
TC: total cholesterol
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